Symptomtext
patient was inadvertently administered a second dose of flu vaccine with no reported adverse event; Initial information received on 23-Mar-2022 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 68 years old male patient who reported patient was inadvertently administered a second dose of flu vaccine with no reported adverse event while receiving vaccines influenza quadrival a-b vaccine [Fluzone Quadrivalent] and influenza quadrival a-b high dose hv vaccine [Fluzone High-Dose Quadrivalent]. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included diphtheria vaccine toxoid, pertussis vaccine acellular 3-component, tetanus vaccine toxoid (boostrix); varicella zoster vaccine rge (cho) (Shingrix) and tozinameran (Pfizer Biontech Covid-19 Vaccine) for Prophylactic vaccination. On 01-Dec-2021, the patient received an unknown dose of suspect influenza quadrival a-b vaccine (strength, formulation was unknown, lot UT7336MA and expiry date: 30-Jun-2022) in the left deltoid in unknown administration site for prophylactic vaccination. On 02-Mar-2022, the patient received 0.7ml dose once of suspect influenza quadrival a-b high dose hv vaccine prefilled syringe (strength, formulation was unknown, lot UJ769AB and expiry date: 30-Jun-2022) via intramuscular route in the left deltoid in unknown administration site for prophylactic vaccination. On 02-Mar-2022 the patient inadvertently administered a second dose of flu vaccine with no reported adverse event (extra dose administered, Latency: 3 months 1 day) following the administration of influenza quadrival a-b high dose hv vaccine and influenza quadrival a-b vaccine. Action taken: not applicable. It was not reported if the patient received a corrective treatment for the event ( Outcome: unknown This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.